The founder of 23andMe, Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company, saying ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

The company’s market value peaked at almost $6 billion after it went public in 2021, but 23andMe reported a 7% decline in revenue and losses of $174 million in the first nine months of its ...